Press releases

Month Year

Email alerts

Mar 17, 2019

New Clinical Trial Shows Medtronic TYRX(TM) Envelope Significantly Reduces Major Infections in Cardiac Implantable Device Patients

Late-Breaking Trial Results Presented at ACC Scientific Sessions and Published in The New England Journal of Medicine

DUBLIN and NEW ORLEANS - March 17, 2019 - Medtronic plc (NYSE:MDT) today announced results from the landmark Worldwide Randomized Antibiotic Envelope Infection Prevention Trial (WRAP-IT), which...
Mar 16, 2019

Medtronic Evolut Low Risk Trial Meets Primary Endpoint

Less Invasive Evolut™ Transcatheter Aortic Valve Replacement (TAVR) System Successful in Clinical Trial When Compared to Open Heart Surgery in Healthier Aortic Stenosis Patients

DUBLIN and NEW ORLEANS – March 16, 2019 – Medtronic plc (NYSE:MDT) today announced first-ever clinical data from the landmark Evolut Low Risk Trial comparing the minimally invasive Evolut™...
Mar 1, 2019

Medtronic Statement Regarding IN.PACT Paclitaxel Safety Analysis Correction Letter in The Journal of the American College of Cardiology

DUBLIN - March 1, 2019 - On February 15, 2019, Medtronic issued a statement regarding a programming error in the clinical data reporting isolated to the two and three year follow-up periods in our...
Feb 26, 2019

Medtronic Resolute(TM) Drug-Eluting Stent (DES) Platform Receives Expanded Indication for Treatment of Chronic Total Occlusion (CTO)

FDA Approval Allows Interventional Cardiologists Access to Resolute DES Technology to Treat De Novo CTO

DUBLIN - February 26, 2019 - Medtronic plc (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) approval of its Resolute Drug-Eluting Stent (DES) platform (including the Resolute...
Feb 15, 2019

Medtronic Statement Regarding Revised IN.PACT Post Market Study Data

DUBLIN - February 15, 2019 - Medtronic plc (NYSE:MDT) today issued the following statement regarding revised clinical study data: Recently, Medtronic became aware of a programming error in the...

Show per page